Amid the 'superbug' crisis, a Big Pharma-backed fund scores a meager raise for antibiotics R&D. Is $140M nearly enough?
Years after Big Pharma abandoned the antibiotics space, a small syndicate has raised $140 million to address the looming threat of antimicrobial resistance — but is it too little, too late?
Back in July, more than 20 biotechs — including heavyweight players Pfizer, Eli Lilly, Novo Nordisk, Boehringer Ingelheim, Bayer Pharmaceuticals, Merck KGaA and the American Merck — banded together to help launch the AMR Action Fund. With an initial $1 billion, the fund set out to bring two to four new antibiotics to patients by 2030.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters
